The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10660 malaria professionals are enjoying the free benefits of MalariaWorld today

anti-malarial drug

Characterisation of plasmodial transketolases and identification of potential inhibitors: an in silico study

December 2, 2020 - 08:00 -- Open Access
Author(s): 
Rita Afriyie Boateng, Özlem Tastan Bishop and Thommas Mutemi Musyoka
Reference: 
Malaria Journal 2020 19:442, 30 November 2020

Plasmodial transketolase (PTKT) enzyme is one of the novel pharmacological targets being explored as potential anti-malarial drug target due to its functional role and low sequence identity to the human enzyme. Despite this, features contributing to such have not been exploited for anti-malarial drug design. Additionally, there are no anti-malarial drugs targeting PTKTs whereas the broad activity of these inhibitors against PTKTs from other Plasmodium spp. is yet to be reported. This study characterises different PTKTs [Plasmodium falciparum (PfTKT), Plasmodium vivax (PvTKT), Plasmodium ovale (PoTKT), Plasmodium malariae (PmTKT) and Plasmodium knowlesi (PkTKT) and the human homolog (HsTKT)] to identify key sequence and structural based differences as well as the identification of selective potential inhibitors against PTKTs.

Global estimation of anti-malarial drug effectiveness for the treatment of uncomplicated Plasmodium falciparum malaria 1991–2019

October 20, 2020 - 16:38 -- Open Access
Author(s): 
Giulia Rathmes, Susan F. Rumisha, Daniel J. Weiss, et al.
Reference: 
Malaria Journal 2020 19:374, 20 October 2020

Anti-malarial drugs play a critical role in reducing malaria morbidity and mortality, but their role is mediated by their effectiveness. Effectiveness is defined as the probability that an anti-malarial drug will successfully treat an individual infected with malaria parasites under routine health care delivery system. Anti-malarial drug effectiveness (AmE) is influenced by drug resistance, drug quality, health system quality, and patient adherence to drug use; its influence on malaria burden varies through space and time.

Assessment of molecular markers of anti-malarial drug resistance among children participating in a therapeutic efficacy study in western Kenya

August 17, 2020 - 13:34 -- Open Access
Author(s): 
Winnie Chebore, Zhiyong Zhou, Simon Kariuki, et al.
Reference: 
Malaria Journal 2020 19:291, 14 August 2020

Anti-malarial drug resistance remains a major threat to global malaria control efforts. In Africa, Plasmodium falciparum remains susceptible to artemisinin-based combination therapy (ACT), but the emergence of resistant parasites in multiple countries in Southeast Asia and concerns over emergence and/or spread of resistant parasites in Africa warrants continuous monitoring. The World Health Organization recommends that surveillance for molecular markers of resistance be included within therapeutic efficacy studies (TES). The current study assessed molecular markers associated with resistance to Artemether−lumefantrine (AL) and Dihydroartemisinin−piperaquine (DP) from samples collected from children aged 6–59 months enrolled in a TES conducted in Siaya County, western Kenya from 2016 to 2017.

Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases

May 19, 2020 - 14:18 -- Open Access
Author(s): 
Cheong DHJ, Daniel Tan WS, Fred Wong WS, Tran T
Reference: 
Pharmacol Res. 2020 May 13:104901

Artemisinins are sesquiterpene lactones with a peroxide moiety that are isolated from the herb Artemisia annua. It has been used for centuries for the treatment of fever and chills, and has been recently approved for the treatment of malaria due to its endoperoxidase properties. Progressively, research has found that artemisinins displayed multiple pharmacological actions against inflammation, viral infections, and cell and tumour proliferation, making them effective against diseases. Moreover, it has displayed a relatively safe toxicity profile.

Rare mutations in Pfmdr1 gene of Plasmodium falciparum detected in clinical isolates from patients treated with anti-malarial drug in Nigeria

September 23, 2019 - 14:42 -- Open Access
Author(s): 
Abel O. Idowu, Wellington A. Oyibo, Sanjib Bhattacharyya, Manjeet Khubbar, Udoma E. Mendie, Violet V. Bumah, Carolyn Black, Joseph Igietseme and Anthony A. Azenabor
Reference: 
Malaria Journal 2019 18:319, 18 September 2019

Plasmodium falciparum, the deadliest causative agent of malaria, has high prevalence in Nigeria. Drug resistance causing failure of previously effective drugs has compromised anti-malarial treatment. On this basis, there is need for a proactive surveillance for resistance markers to the currently recommended artemisinin-based combination therapy (ACT), for early detection of resistance before it become widespread.

Country: 
Medical Condition: 

Cellular engineering of Artemisia annua and Artemisia dubia with the rol ABC genes for enhanced production of potent anti-malarial drug artemisinin

May 6, 2016 - 17:55 -- Open Access
Author(s): 
Bushra Hafeez Kiani, John Suberu and Bushra Mirza
Reference: 
Malaria Journal 2016 15:252, 4 May 2016

Transformation of Artemisia sp. with rol ABC genes can lead to the increased production of artemisinin, which will help to meet the increasing demand of artemisinin because of its diverse pharmacological and anti-malarial importance.

Subscribe to RSS - anti-malarial drug